Supplementary Tables 1-17, Figures 1-14, Methods from Gene Signature–Guided Dasatinib Therapy in Metastatic Breast Cancer
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Table 1: Probe sets used in dasatinib 19-gene dasatinib target index. Supplemental Table 2: Probe sets used in Src Pathway index. Supplemental Table 3: Probe sets used in the Cell Line Derived Sensitivity predictor. Supplemental Table 4: Agreement between predictors. Supplemental Table 5: QC metrics for the 39 FNA samples used for replicate hybridization (technical replicates). Supplemental Table 6: QC metrics for the 37 paired FNA/CBX samples and 6 replicate CBX samples. Supplemental Table 7: Concordance correlation coefficients for prediction scores. Supplemental Table 8: Prediction results on 39 FNA pairs. Supplemental Table 9: Prediction results on 37 FNA/CBX pairs. Supplemental Table 10: Prediction results on 6 CBX pairs. Supplemental Table 11: Prediction results for the 133 breast cancer samples. Supplemental Table 12: Concordance correlation coefficients with revised average expression-based Src pathway. Supplemental Table 13: Prediction results on 39 FNA pairs (revised Src pathway). Supplemental Table 14: Prediction results on 37 FNA/CBX pairs (revised Src pathway. Supplemental Table 15: Prediction results on 6 CBX pairs (revised Src pathway). Supplemental Table 16: Individual prediction scores for the 23 BMS cell lines. Supplementary Table 17. Clinical characteristics of the 133 patients included in the training data set. Supplemental Figure 1: Overall index distribution of Dasatinib 19-gene target index. Supplemental Figure 2: Agreements between 3 predictors. Supplemental Figure 3: Replicate FNA (N=39). Supplemental Figure 4: Matching FNA/CBX pairs from same tumor (N=37). Supplemental Figure 5: FNA/CBX cohort pairs (N=29). Supplemental Figure 6: FNA/CBX ANON pairs (N=8). Supplemental Figure 7: CBX pairs from same tumor (N=6). Supplemental Figure 8: Concordance for 39 FNA pairs using expression values of individual probes. Supplemental Figure 9: Concordance for 39 FNA pairs using the expression values of subset probes. Supplemental Figure 10:Multi-Dimension Scaling (MDS) analysis with the cell lines used to develop the Src index and the MDACC 133 patients. Supplemental Figure 11. Revised SRC Pathway activity score distribution in the reference population. Supplemental Figure 12 Overlap between the 3 different prediction results. Supplemental Figure 13: Dasatinib 19-genes target index on 23 BMS cell lines with known dasatinib sensitivity. Supplemental Figure 14: Revised Src pathway score on 23 BMS cell lines with known dasatinib sensitivity.
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362398325